Rigel Pharmaceuticals, Inc

(NASDAQ:RIGL)

Latest On Rigel Pharmaceuticals, Inc (RIGL):

Date/Time Type Description Signal Details
2023-05-26 15:54 ESTNewsRigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive GrowthN/A
2023-05-03 02:14 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2MN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 01:42 ESTNewsRigel Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-27 09:21 ESTNewsRigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For ProfitabilityN/A
2023-04-04 02:31 ESTNewsRigel Pharma begun at neutral at Piper Sandler on value creation potentialN/A
2023-03-09 06:02 ESTNewsRigel Pharmaceuticals' Challenges Continue To Outweigh Potential UpsideN/A
2023-03-08 00:02 ESTNewsRigel Pharma, with beats on quarterly top and bottom lines, surges 19%N/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04MN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 18:38 ESTNewsRigel Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-28 01:25 ESTNewsRigel Pharmaceuticals (RIGL) Investor Presentation - SlideshowN/A
2023-01-09 20:04 ESTNewsRigel Pharma rises as preliminary Q4 revenue above estimatesN/A
2022-12-31 03:48 ESTNewsRigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023N/A
2022-12-22 20:32 ESTNewsRigel launches leukemia therapy in U.S.N/A
2022-12-15 15:09 ESTNewsRigel extends gains as dosing starts in early-stage trial for blood cancer therapyN/A
2022-12-03 04:05 ESTNewsRigel upgraded at Citi on bullish outlook for new leukemia drugN/A
2022-12-02 10:34 ESTNewsRigel stock soars 40% on FDA approval of blood cancer drug RezlidhiaN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21MN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 22:35 ESTNewsRigel Pharma gains as analysts play down setback for COVID-19 therapyN/A
2022-10-31 23:15 ESTNewsRigel Pharmaceuticals Provides An Opportunity For Investors Or An AcquirerN/A
2022-10-11 06:01 ESTNewsRigel cutting 16% of workforce after declining to file sNDA for fostamatinibN/A
2022-08-18 23:47 ESTNewsRigel Pharma adds ~7% to reach over two month highN/A
2022-08-04 01:22 ESTNewsRigel rises 17% on strong Q2 resultN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-02 20:22 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17MN/A
2022-08-02 05:27 ESTNewsRigel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-10 02:16 ESTNewsRigel Pharma downgraded at several street firms following anemia study failureN/A
2022-06-09 00:09 ESTNewsRigel stock crashes 48% as fostamatinib fails phase 3 anemia studyN/A
2022-06-09 00:08 ESTNewsRigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock valueN/A
2022-05-31 10:56 ESTNewsRigel Pharmaceuticals: A Status CheckN/A
2022-05-04 11:44 ESTNewsRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-03 19:55 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8MN/A
2022-05-03 19:54 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-03 01:40 ESTNewsRigel Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 20:19 ESTNewsRigel Pharmaceuticals grants stock options to employeesN/A
2022-03-22 02:13 ESTNewsRigel Pharmaceuticals: Why The Stock Is On A RunN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79MN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-28 17:57 ESTNewsRigel Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 13:56 ESTNewsRigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetN/A
2022-01-11 00:53 ESTNewsRigel down as it expects slight decrease in products sales in Q4 compared to prior yearN/A
2021-12-22 03:23 ESTNewsRigel Pharma says its trial for bleeding disorder therapy met main goal in JapanN/A
2021-11-30 10:44 ESTNewsRigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveN/A

About Rigel Pharmaceuticals, Inc (RIGL):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

See Advanced Chart

General

  • Name Rigel Pharmaceuticals, Inc
  • Symbol RIGL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 169
  • Last Split Factor1:9
  • Last Split Date2003-06-25
  • Fiscal Year EndDecember
  • IPO Date2000-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.rigel.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.34
  • Price/Book (Most Recent Quarter) 20.39
  • Enterprise Value Revenue 6.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.02
  • Next Year EPS Estimate -$0.20
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -27%
  • Operating Margin -27%
  • Return on Assets -14%
  • Return on Equity -68%
  • Revenue 108.62 million
  • Earnings Per Share -$0.35
  • Revenue Per Share $0.64
  • Gross Profit 47.63 million
  • Quarterly Earnings Growth 19.8%
View More

Highlights

  • Market Capitalization 689.52 million
  • EBITDA -60896000
  • PE Ratio -16.62
  • PEG Ratio -0.1
  • Analyst Target Price $8.5
  • Book Value Per Share $0.20
View More

Share Statistics

  • Shares Outstanding 170.04 million
  • Shares Float 169.52 million
  • % Held by Insiders 31%
  • % Held by Institutions 85.26%
  • Shares Short 16.81 million
  • Shares Short Prior Month 19.36 million
  • Short Ratio 3.15
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.45
  • 52 Week High $5.5
  • 52 Week Low $1.26
  • 50 Day Moving Average 4.2
  • 200 Day Moving Average 3.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rigel Pharmaceuticals, Inc (RIGL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$18.45 million-$0.11-$0.113.51%
2020-09-302020-11-05$18.39 million-$0.08-$0.1234.05%
2020-06-302020-08-04$16.02 million-$0.10-$0.1426.09%
2020-03-312020-05-05$55.76 million$0.13$0.13-1.59%
2019-12-312020-02-27$15.4 million-$0.10-$0.1217.56%
2019-09-302019-11-05$20.86 million-$0.07-$0.1032.69%
2019-06-302019-08-06$10.41 million-$0.12-$0.1412.22%
2019-03-312019-05-07$12.62 million-$0.11-$0.1315.38%
2018-12-312019-02-28$37.86 million$0.02$0.03-41.35%
2018-09-302018-11-06$4.87 million-$0.14-$0.157.83%
2018-06-302018-08-08$1.79 million-$0.16-$0.16-0.19%
2018-03-312018-05-01$N/A-$0.17-$0.183.41%
2017-12-312018-03-06$3.58 million-$0.18-$0.13-35.03%
2017-09-302017-11-07$900000-$0.14-$0.158.32%
2017-06-302017-08-01$-3584000-$0.16-$0.14-12.76%
2017-03-312017-05-02$3.58 million-$0.13-$0.12-5.18%
2016-12-312017-03-07$3 million-$0.16-$0.175.33%
2016-09-302016-11-01$3.76 million-$0.24-$0.23-3.99%
2016-06-302016-08-02$8.59 million-$0.15-$0.2026.33%
2016-03-312016-05-03$5.03 million-$0.19-$0.219.18%
2015-12-312016-03-08$8.54 million-$0.14-$0.14-3.47%
2015-09-302015-11-03$13 million-$0.08-$0.1752.94%
2015-06-302015-08-04$5.18 million-$0.16-$0.2227.27%
2015-03-312015-05-07$2.18 million-$0.21-$0.18-16.67%
2014-12-312015-03-03$8.25 million-$0.15-$0.2642.31%
2014-09-302014-11-04$N/A-$0.24-$0.2711.11%
2014-06-302014-08-05$N/A-$0.29-$0.25-16%
2014-03-312014-05-07$N/A-$0.25-$0.250%
2013-12-312014-03-04$5.75 million-$0.19-$0.2524%
2013-09-302013-11-05$-1400000-$0.25-$0.2913.79%
2013-06-302013-08-06$1.4 million-$0.26-$0.3013.33%
2013-03-312013-05-07$N/A-$0.29-$0.303.33%
2012-12-312013-03-05$2.25 million-$0.30-$0.326.25%
2012-09-302012-11-06$-1500000-$0.36-$0.372.7%
2012-06-302012-08-07$1.5 million-$0.35-$0.350%
2012-03-312012-05-01$750000-$0.32-$0.31-3.23%
2011-12-312012-03-06$395000-$0.36-$0.28-28.57%
2011-09-302011-11-01$4.36 million-$0.25-$0.3016.67%
2011-06-302011-08-02$395000-$0.37-$0.382.63%
2011-03-312011-05-03$N/A-$0.40-$0.36-11.11%
2010-12-312011-03-01$52.72 million-$0.33-$0.368.33%
2010-09-302010-11-02$72.28 million$0.96$0.6254.84%
2010-06-302010-08-03$49.46 million$0.51$0.478.51%
2010-03-312010-05-04$3.26 million-$0.43$0.11-490.91%
2009-12-312010-03-02$750000-$0.48-$0.45-6.67%
2009-09-302009-11-03$N/A-$0.70-$0.58-20.69%
2009-06-302009-08-04$N/A-$0.81-$0.810%
2009-03-312009-05-05$N/A-$0.82-$0.9917.17%
2008-12-312009-02-24$N/A-$0.91-$0.976.19%
2008-09-302008-11-03$N/A-$1.03-$0.87-18.39%
2008-06-302008-08-05$N/A-$0.93-$0.69-34.78%
2008-03-312008-05-06$N/A-$0.79-$0.62-27.42%
2007-12-312008-02-12$8 million-$0.61-$0.43-41.86%
2007-09-302007-11-06$-1956000-$0.61-$0.57-7.02%
2007-06-302007-08-07$1.96 million-$0.68-$0.63-7.94%
2007-03-312007-05-10$2.64 million-$0.68-$0.67-1.49%
2006-12-312007-02-06$3.13 million-$0.62-$0.643.13%
2006-09-302006-11-07$6.13 million-$0.46-$0.472.13%
2006-06-302006-08-02$14.32 million-$0.09-$0.5683.93%
2006-03-312006-05-02$9.9 million-$0.34-$0.32-6.25%
2005-12-312006-02-07$6.02 million-$0.36-$0.4316.28%
2005-09-302005-11-08$3.28 million-$0.56-$0.618.2%
2005-06-302005-08-03$4.61 million-$0.62-$0.7112.68%
2005-03-312005-05-03$2.62 million-$0.57-$0.48-18.75%
2004-12-312005-02-08$1.1 million-$0.75-$0.69-8.7%
2004-09-302004-11-05$659000-$0.88-$0.71-23.94%
2004-06-302004-08-03$1.49 million-$0.68-$0.748.11%
2004-03-312004-05-04$1.49 million-$0.81-$0.78-3.85%
2003-12-312004-02-03$2.11 million-$0.80-$0.71-12.68%
2003-09-302003-11-05$2.1 million-$0.78
2003-06-302003-08-05$2.35 million-$1.90
2003-03-312003-05-06$4.5 million-$1.53
2002-12-312003-02-05$3.7 million-$1.62-$2.1625%
2002-09-302002-11-04$3.65 million-$1.98-$1.80-10%
2002-06-302002-08-06$4.34 million-$2.07-$1.35-53.33%
2002-03-312002-05-07$4.1 million-$1.71-$1.53-11.76%
2001-12-312002-02-05$4.78 million-$1.44-$1.8421.74%
2001-09-302001-11-07$4.21 million-$1.53-$1.530%
2001-06-302001-08-08$3.12 million-$1.80-$0.99-81.82%
2001-03-312001-05-08$3.19 million-$0.99-$1.4431.25%
2000-12-312001-02-07$3.21 million-$3.24-$2.34-38.46%

Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rigel Pharmaceuticals, Inc (RIGL) Chart:

Rigel Pharmaceuticals, Inc (RIGL) News:

Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rigel Pharmaceuticals, Inc (RIGL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2030CALL0 0563.8TRUE00
2025-06-2050CALL0 0432.27TRUE00
2025-06-2070CALL0 0638.88TRUE00
2025-06-2080CALL0 8294.88TRUE00
2025-06-2090CALL0 1247.86TRUE00
2025-06-20100CALL0 6242.79TRUE00
2025-06-20110CALL0 0409.66TRUE00
2025-06-20120CALL0 0357.98TRUE00
2025-06-20130CALL0 3106.15TRUE00
2025-06-20140CALL0 7250.77TRUE00
2025-06-20155CALL0 23141.33TRUE00
2025-06-20160CALL0 2109.14TRUE00
2025-06-20173.7CALL50 2884.32TRUE3.70
2025-06-20180CALL0 3072.12TRUE00
2025-06-20192.05CALL0 21112.55TRUE00
2025-06-20201.56CALL2 5176.88TRUE0.460.42
2025-06-20211.22CALL1 17583.64FALSE0.280.3
2025-06-20221.2CALL0 1761.07FALSE00
2025-06-20230CALL0 15179.58FALSE00
2025-06-20240CALL0 9173.08FALSE00
2025-06-20250.3CALL0 46112.86FALSE00
2025-06-20260CALL0 7198.87FALSE00
2025-06-20270CALL0 77250.49FALSE00
2025-06-20280.05CALL0 4156.11FALSE00
2025-06-20290CALL0 0274.2FALSE00
2025-06-20300.07CALL0 39104.36FALSE00
2025-06-20310CALL0 0295.22FALSE00
2025-06-20320CALL0 0304.91FALSE00
2025-06-20330CALL0 0282.96FALSE00
2025-06-20340CALL0 0322.89FALSE00
2025-06-20350CALL0 5121.05FALSE00
2025-06-20360CALL0 1339.31FALSE00
2025-06-20370CALL0 11347FALSE00
2025-06-20380.03CALL0 27354.39FALSE00
2025-06-20400CALL0 11132.06FALSE00
2025-06-2030PUT0 20FALSE00
2025-06-2050PUT0 3982.22FALSE00
2025-06-2070PUT0 0656.11FALSE00
2025-06-2080PUT0 0505.19FALSE00
2025-06-2090PUT0 0586.99FALSE00
2025-06-20100PUT0 0468.85FALSE00
2025-06-20110PUT0 0363.48FALSE00
2025-06-20120PUT0 7428.69FALSE00
2025-06-20130PUT0 2340.78FALSE00
2025-06-20140.05PUT0 2347.35FALSE00
2025-06-20150PUT0 14235.19FALSE00
2025-06-20160PUT0 21158.18FALSE00
2025-06-20170.35PUT33 34991.7FALSE0.150.75
2025-06-20180.51PUT0 15588.12FALSE00
2025-06-20191PUT0 1266.27FALSE00
2025-06-20201.89PUT0 369.19FALSE00
2025-06-20210PUT0 771.28TRUE00
2025-06-20220PUT0 084.47TRUE00
2025-06-20230PUT0 3103.3TRUE00
2025-06-20240PUT0 0112.09TRUE00
2025-06-20250PUT0 0190.11TRUE00
2025-06-20260PUT0 0109.24TRUE00
2025-06-20270PUT0 076.05TRUE00
2025-06-20280PUT0 0129.72TRUE00
2025-06-20290PUT0 0117.04TRUE00
2025-06-20300PUT0 0117.93TRUE00
2025-06-20310PUT0 0139.37TRUE00
2025-06-20320PUT0 0111.3TRUE00
2025-06-20330PUT0 0139.3TRUE00
2025-06-20340PUT0 0160.98TRUE00
2025-06-20350PUT0 0167.59TRUE00
2025-06-20360PUT0 0166.55TRUE00
2025-06-20370PUT0 0193.15TRUE00
2025-06-20380PUT0 0169.59TRUE00
2025-06-20400PUT0 0180.29TRUE00
2025-07-18110CALL0 0104.82TRUE00
2025-07-18120CALL0 099.42TRUE00
2025-07-18130CALL0 067.71TRUE00
2025-07-18140CALL0 089.39TRUE00
2025-07-18150CALL0 094.25TRUE00
2025-07-18160CALL0 099.36TRUE00
2025-07-18170CALL0 069.23TRUE00
2025-07-18182.82CALL0 671.3TRUE00
2025-07-18190CALL0 092.58TRUE00
2025-07-18202.35CALL6 074.38TRUE2.350
2025-07-18211.6CALL1 063.73FALSE1.60
2025-07-18220CALL0 179.54FALSE00
2025-07-18230CALL0 0113.06FALSE00
2025-07-18240CALL0 0118.13FALSE00
2025-07-18250CALL0 0123.94FALSE00
2025-07-18260.45CALL0 1130.73FALSE00
2025-07-18270.35CALL0 11133.12FALSE00
2025-07-18280CALL0 0142.37FALSE00
2025-07-18110PUT0 0260.13FALSE00
2025-07-18120PUT0 0234.1FALSE00
2025-07-18130PUT0 0178.29FALSE00
2025-07-18140PUT0 0188.38FALSE00
2025-07-18150PUT0 1167.84FALSE00
2025-07-18160PUT0 0148.42FALSE00
2025-07-18170PUT0 0134.1FALSE00
2025-07-18180PUT0 0107.74FALSE00
2025-07-18192.05PUT0 797.7FALSE00
2025-07-18200PUT0 074FALSE00
2025-07-18210PUT0 077.46TRUE00
2025-07-18220PUT0 086.4TRUE00
2025-07-18230PUT0 046.07TRUE00
2025-07-18240PUT0 077.72TRUE00
2025-07-18250PUT0 067.34TRUE00
2025-07-18260PUT0 088.32TRUE00
2025-07-18270PUT0 086.55TRUE00
2025-07-18280PUT0 088.15TRUE00
2025-09-1930CALL0 0229.29TRUE00
2025-09-1950CALL0 0125.87TRUE00
2025-09-1990CALL0 0105.2TRUE00
2025-09-19100CALL0 0101.06TRUE00
2025-09-19110CALL0 088.89TRUE00
2025-09-19120CALL0 187.32TRUE00
2025-09-19130CALL0 597.82TRUE00
2025-09-19140CALL0 288.06TRUE00
2025-09-19156.1CALL0 385.74TRUE00
2025-09-19160CALL0 1083.91TRUE00
2025-09-19170CALL0 072.49TRUE00
2025-09-19180CALL0 374.6TRUE00
2025-09-19193.74CALL0 878.8TRUE00
2025-09-19202.7CALL0 679.09TRUE00
2025-09-19210CALL0 381.19FALSE00
2025-09-19222.25CALL0 4987.95FALSE00
2025-09-19230CALL0 8685.32FALSE00
2025-09-19241.97CALL0 3284.21FALSE00
2025-09-19251.3CALL0 7977.74FALSE00
2025-09-19300.8CALL0 5675.95FALSE00
2025-09-19350.5CALL4 3975.26FALSE0.150.43
2025-09-1930PUT0 2640.47FALSE00
2025-09-1950PUT0 0392.74FALSE00
2025-09-1990PUT0 2209.08FALSE00
2025-09-19100PUT0 0190.3FALSE00
2025-09-19110PUT0 0140.11FALSE00
2025-09-19120PUT0 0135.12FALSE00
2025-09-19130PUT0 2129.61FALSE00
2025-09-19140PUT0 2129.7FALSE00
2025-09-19150PUT0 2791.7FALSE00
2025-09-19161.66PUT0 2108.93FALSE00
2025-09-19170PUT0 5107.88FALSE00
2025-09-19180PUT0 1092.98FALSE00
2025-09-19190PUT0 682.89FALSE00
2025-09-19203.64PUT0 674.98FALSE00
2025-09-19210PUT0 075.65TRUE00
2025-09-19220PUT0 078.1TRUE00
2025-09-19230PUT0 072.81TRUE00
2025-09-19240PUT0 076.31TRUE00
2025-09-19250PUT0 081.45TRUE00
2025-09-19300PUT0 075TRUE00
2025-09-19350PUT0 081.78TRUE00
2025-12-1930CALL0 0188.83TRUE00
2025-12-1950CALL0 1127.35TRUE00
2025-12-1990CALL0 094.6TRUE00
2025-12-19100CALL0 088.29TRUE00
2025-12-19110CALL0 093.98TRUE00
2025-12-19120CALL0 081.61TRUE00
2025-12-19130CALL0 388.75TRUE00
2025-12-19140CALL0 075.98TRUE00
2025-12-19150CALL0 480.3TRUE00
2025-12-19160CALL0 1274.07TRUE00
2025-12-19170CALL0 280.21TRUE00
2025-12-19180CALL0 178.07TRUE00
2025-12-19195.21CALL0 769.94TRUE00
2025-12-19200CALL0 1583.07TRUE00
2025-12-19210CALL0 273.24FALSE00
2025-12-19220CALL0 2278.56FALSE00
2025-12-19230CALL0 9868.61FALSE00
2025-12-19240CALL0 174.95FALSE00
2025-12-19252.89CALL0 477.94FALSE00
2025-12-19262.87CALL0 074.7FALSE00
2025-12-19271.95CALL1 163.24FALSE1.950
2025-12-19281.94CALL1 066.64FALSE1.940
2025-12-19301.75CALL0 2477.77FALSE00
2025-12-1930PUT0 0384.33FALSE00
2025-12-1950PUT0 0255.31FALSE00
2025-12-1990PUT0 1129.44FALSE00
2025-12-19100PUT0 1119.04FALSE00
2025-12-19110PUT0 1111.25FALSE00
2025-12-19120PUT0 1109.15FALSE00
2025-12-19130PUT0 2106.41FALSE00
2025-12-19140PUT0 0104.45FALSE00
2025-12-19150PUT0 099.64FALSE00
2025-12-19160PUT0 190.91FALSE00
2025-12-19170PUT0 278.96FALSE00
2025-12-19183.6PUT0 372.44FALSE00
2025-12-19194.07PUT0 277.28FALSE00
2025-12-19200PUT0 168.28FALSE00
2025-12-19210PUT0 071.19TRUE00
2025-12-19220PUT0 070.02TRUE00
2025-12-19230PUT0 071.66TRUE00
2025-12-19240PUT0 076.14TRUE00
2025-12-19250PUT0 071.79TRUE00
2025-12-19260PUT0 076.27TRUE00
2025-12-19270PUT0 080.45TRUE00
2025-12-19280PUT0 080.93TRUE00
2025-12-19300PUT0 074.63TRUE00

Latest RIGL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST200$0.6924
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST500$0.6924
Jun 13, 2022 7:59 PM EST850$0.6921

Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm
2019-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm
2020-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm
2018-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm
2019-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm
2020-08-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm
2018-06-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2020-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm
2019-03-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm

Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 31%
Institutional Ownership: 8526%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02Anne-Marie DuliegeEVP & Chief Medical OfficerSell5,000.002.7913,932.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerSell16,500.003.5157,860.550.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerSell115,500.003.50404,250.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-08-23Eldon C. III MayerEVP & Chief Commercial OfficerBuy100,000.002.82282,320.00115,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy115,500.002.54293,370.00115,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerBuy16,500.002.5441,910.0016,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-10Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.28164,210.00165,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-08-17RAUL R RODRIGUEZCEO, PresidentBuy114,000.002.63300,002.40173,519.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-09-11Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.23161,340.00215,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy37,500.002.1179,125.0037,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy46,726.002.1399,573.1146,726.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy3,274.002.136,971.0050,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2018-10-12Nelson CabatuanPrincipal Accounting OfficerSell10,000.003.1231,200.0058.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm